Evidence mapPaperPMID 37408009Full record

ArticleJournal of health, population, and nutrition2023

Differences in prevalence and management of chronic kidney disease among T2DM inpatients at the grassroots in Beijing and Taiyuan: a retrospective study.

Lingwang An, Dandan Wang, Xiaorong Shi, Yali He, Yaujiunn Lee, Juming Lu

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of health, population, and nutrition, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07547878 (A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07547878 phase4not yet recruitingstarted 2026, after this paper: background citation

A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes: RAPID-CKD

Ran2026Enrolled64Registered outcomes18Posted comparisons0ConditionsChronic Kidney Disease, Type 2 DiabetesArmsAccupril, Aceon, Altace, Atacand, Avapro
Open the trial in the graph
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Lingwang AnDepartment of Endocrinology, Beijing Ruijing Diabetes Hospital, Beijing, 100079, China.
Dandan WangDepartment of Endocrinology, Beijing Ruijing Diabetes Hospital, Beijing, 100079, China.
Xiaorong ShiDepartment of Endocrinology, Taiyuan Diabetes Hospital, Taiyuan, 030013, China.
Yali HeDepartment of Endocrinology, Taiyuan Diabetes Hospital, Taiyuan, 030013, China.
Yaujiunn LeeDepartment of Metabolism and Endocrinology, Lee's Clinic, Pingtung, 90000, Taiwan, China.
Juming LuDepartment of Endocrinology, Beijing Ruijing Diabetes Hospital, Beijing, 100079, China. lujm666_1@21cn.com.
Beijing Shijingshan Hospital · CNTaiyuan Central Hospital · CNPeking University · CNPingtung Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeChronic kidney disease (CKD) has been one of the most common complications in type 2 diabetes mellitus (T2DM) patients. This retrospective study aimed to investigate the regional differences in the prevalence and management of CKD in T2DM inpatients from two grassroots hospitals in Beijing and Taiyuan.

methodsThe sociodemographic status, health history, lifestyle information, biochemical parameters and drug choices of the patients were collected from the Diabetes Care Information System using a retrospective cross-sectional analysis. The presence of CKD was defined as albuminuria (urine albumin-to-creatinine ratio of ≥ 30 mg/g) and/or as a reduced estimated glomerular filtration rate (< 60 ml/min/1.73 m

results858 patients with T2DM in Beijing and 1,085 patients with T2DM in Taiyuan were included, with a median age of 61.0 and 61.9 years, respectively. The duration of diabetes was 10.5 and 10.3 years, respectively. The prevalence of CKD in Beijing (39.2%) was significantly higher than in Taiyuan (22.4%). The overall ABC control (A = haemoglobin A

conclusionsThe higher prescription rates of RAAS inhibitors, SGLT-2i and dyslipidaemia therapy may underlie the fluctuations in the prevalence of CKD in Beijing or Taiyuan. Intensive insulin therapy and personal nutritional guidance, along with the extensive use of RAAS inhibitors, SGLT-2i and dyslipidaemia therapy during follow-up, can all play a positive role in the management of CKD in patients with T2DM in both Beijing and Taiyuan.

Indexed as

Diabetes Mellitus, Type 2InsulinsRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsCross-Sectional StudiesHumansInpatientsMiddle AgedPrevalenceRetrospective StudiesInsulinsSodium-Glucose Transporter 2 InhibitorsChronic kidney disease (CKD)Dietary assessmentRegional differencesType 2 diabetes mellitus (T2DM)

Identifiers

PMID37408009
PMCPMC10320918
OpenAlexW4383224568

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.